PolyPid PYPD 深 沪

Preview: PolyPid's Earnings

PolyPid (NASDAQ:PYPD) is set to give its latest quarterly earnings report on We...

02-11 04:02

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PolyPid secured $26.7 million through warrant exercises, extending its runway beyond FDA approval of D-PLEX₁₀₀. The product demonstrated significant reduction in surgical site infections in Phase 3 SHIELD II trial.

2025-06-16 23:20

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid Ltd. announced positive results from its pivotal SHIELD II Phase 3 trial of D-PLEX 100, demonstrating statistically significant reductions in surgical site infections and meeting both primary and key secondary endpoints. The company plans to submit an NDA to the FDA in early 2026.

2025-06-09 11:30

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

2025-06-06 20:05

PolyPid Wraps Up Phase 3 Enrollment For D-PLEX100, Eyes FDA Submission Following Q2 Top-Line Data

The Company anticipates reporting top-line results by the end of the second quarter of 2025. If the Phase 3 data are positive, PolyPid expects to submit a New Drug Application ("NDA") to the U.S. Food and Drug

2025-03-11 19:57

PolyPid Files for Potential Sale of 3.9 Million Shares

05:03 PM EDT, 08/30/2024 (MT Newswires) -- PolyPid (PYPD) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to 3.9 million ordinary shares. The filing covers 2 million ordinary shares held by the selling shareholders, 1.7 million shares...

2024-08-31 05:03

PolyPid Files For Resale Of Up To 3.9M Ordinary Shares By Selling Shareholders

PolyPid Files For Resale Of Up To 3.9M Ordinary Shares By Selling Shareholders

2024-08-31 04:04